Nov 1, 2017 – Gamida Cell, a leading cellular and immune therapeutics company based in Jerusalem, announced that two oral presentations on new data from the company’s pipeline programs is presenting during the 59th Annual Meeting of the American Society for Hematology (ASH).

The oral presentations highlight safety and efficacy data for a completed phase 2 study of the company’s lead clinical asset, NiCord, as a single cord blood graft. NiCord’s phase 2 study is proof-of-concept data for the advancement of natural killer cells (NK cells) as an immunotherapeutic modality for patients with cancer. These abstracts are now available on the ASH conference website.

For more information, see Businesswire http://www.businesswire.com/news/home/20171101005596/en/Gamida-Cell-Present-New-Data-Key-Programs